Trial Profile
Pharmacokinetics of Anidulafungin (Ecalta) Given Intravenously as Prophylaxis to Obese Patients With Risk of Invasive Fungal Infection Undergoing Gastric Bypass Surgery
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Anidulafungin (Primary)
- Indications Mycoses
- Focus Pharmacokinetics
- Acronyms ADOPT
- 03 May 2016 Results published in the Clinical Pharmacokinetics
- 27 Oct 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to completed.
- 20 Jun 2014 Planned End Date changed from 1 Dec 2014 to 1 Mar 2015.